Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma characterized by the presence of large, atypical lymphoid cells. The ALK-positive variant is associated with a specific genetic alteration involving the anaplastic lymphoma kinase gene. This condition primarily affects lymph nodes in the axilla and upper limb, leading to significant clinical implications, including potential systemic symptoms and treatment challenges. Accurate coding with ICD-10 Code C84.64 is essential for proper diagnosis, documentation, medical billing, and public health reporting.
ICD-10 Code C84.64 designates anaplastic large cell lymphoma, ALK-positive, specifically affecting the lymph nodes of the axilla and upper limb. This code is used when documenting cases of ALCL that exhibit the ALK gene alteration, which is crucial for determining treatment options and prognosis. It should be applied in clinical documentation and billing when the diagnosis is confirmed through histopathological examination.
Anaplastic large cell lymphoma (ALCL), ALK-positive, is a hematological malignancy that arises from T-cell lineage and is characterized by the presence of large, atypical lymphoid cells. The ALK-positive variant is associated with a chromosomal translocation that leads to the overexpression of the ALK protein, contributing to tumorigenesis. This condition requires prompt medical attention due to its aggressive nature and potential for systemic involvement.
ICD-10 Code C84.64 is utilized in SOAP notes to document the diagnosis of anaplastic large cell lymphoma, ALK-positive, affecting the axillary and upper limb lymph nodes. This code plays a critical role in capturing the patient's symptoms, assessment findings, and treatment plans, ensuring comprehensive documentation in both acute and chronic care settings.
In SOAP notes, ICD-10 Code C84.64 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of anaplastic large cell lymphoma, ALK-positive. This code is essential for ensuring continuity of care, supporting accurate billing, and meeting electronic health record documentation standards.
The management of anaplastic large cell lymphoma, ALK-positive, typically involves a combination of chemotherapy and targeted therapies. Hospitalization may be required for intensive treatment and monitoring.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code C84.64 is critical in medical billing, particularly in hospital, emergency room, or infectious disease care settings.
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous, push technique, each additional substance. |
| 85025 | Complete blood count (CBC) with automated differential white blood cell count. |
| 77021 | Magnetic resonance imaging (MRI) of the lymphatic system. |
| 99214 | Established patient office visit, moderate complexity. |
Common Questions About Using ICD-10 Code C84.64 for Anaplstc lg cell lymph, ALK-pos, nodes of axla and upr limb
What are the common symptoms of ALK-positive anaplastic large cell lymphoma?
Common symptoms include swollen lymph nodes, fever, night sweats, unexplained weight loss, and fatigue. Patients may also experience localized pain or discomfort in affected areas.
How is anaplastic large cell lymphoma diagnosed?
Diagnosis typically involves a biopsy of the affected lymph nodes, followed by histopathological examination to identify the presence of large atypical lymphoid cells and ALK positivity through immunohistochemistry.
What treatment options are available for ALK-positive anaplastic large cell lymphoma?
Treatment usually includes chemotherapy regimens, such as CHOP, and may involve targeted therapies that specifically address the ALK gene alteration. Clinical trials may also be an option for eligible patients.
Is anaplastic large cell lymphoma curable?
The prognosis for ALK-positive anaplastic large cell lymphoma can be favorable with appropriate treatment, especially in early-stage disease. However, outcomes vary based on individual patient factors and disease characteristics.
Clinical Notes
SOAP notes
DAP notes
AI medical notes